lutetium (177Lu) oxodotreotide
177Lu-DOTATATE, 177Lu-DOTA-TATE, [177Lu-DOTA0,Tyr3]octreotate, lutetium Lu 177 dotatate, 177Lu-DOTA0-Tyr3-octreotate, oxodotreotide
Lutetium-177 dotatate is a radiolabelled somatostatin analogue, a genuine peptide therapeutic, used for peptide receptor radionuclide therapy of somatostatin-receptor-positive neuroendocrine tumours. An eight-amino-acid octreotide derivative delivers a beta-emitting radionuclide directly into tumour cells, which then internalise and trap it. It produces some of the most striking progression-free survival results in neuroendocrine oncology, though the overall survival picture is more complicated than the headline figures suggest.
Mechanism
The targeting vector is octreotate ([Tyr³]octreotate), an eight-residue cyclic analogue of somatostatin, joined at its N-terminus to the macrocyclic chelator DOTA. Octreotate binds somatostatin receptor subtype 2 (SSTR2) with very high affinity, with lesser affinity for SSTR5 and minimal binding to SSTR1, 3 and 4. Well-differentiated gastroenteropancreatic and bronchial neuroendocrine tumours overexpress SSTR2 by one to two orders of magnitude relative to normal tissue, which is what makes the strategy work at all. Compared with octreotide, octreotate substitutes threonine for threoninol at the C-terminus, giving a free carboxylic acid and a reported sixfold to ninefold higher SSTR2 affinity.
On binding, the peptide-receptor complex is internalised by clathrin-mediated endocytosis and routed to lysosomes. Here the design of DOTA becomes critical: the macrocyclic cage holds Lu³⁺ so tightly that the radiometal cannot escape even in the acidic, proteolytic lysosomal environment, and because Lu³⁺ is a charged, hydrophilic species it cannot diffuse back across the membrane. The radionuclide is therefore residualised, trapped inside the tumour cell for as long as the cell survives. Lutetium-177 decays by beta-minus emission with a maximum energy of 498 keV and a mean tissue range of about 0.67 mm (maximum around 2 mm), depositing energy that generates single- and double-strand DNA breaks in the target cell and, through crossfire, in immediate neighbours. Lutetium-177 also emits gamma photons at 113 and 208 keV, which allows post-therapy SPECT imaging and patient-specific dosimetry, and pairs it with gallium-68 dotatate as one half of a true theranostic pair, where the same targeting molecule is used first to select patients and then to treat them.
What the research shows
NETTER-1 randomised 229 patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours to four cycles of lutetium-177 dotatate plus long-acting octreotide 30 mg, or to high-dose long-acting octreotide 60 mg. The progression-free survival result was extraordinary: at the interim analysis, estimated 20-month progression-free survival was 65.2% versus 10.8%, with a hazard ratio of 0.21, and the eventual median was 28.4 versus 8.5 months. Response rate was 18% versus 3%. Health-related quality of life measures also favoured the treatment arm. NETTER-2 subsequently tested the approach as first-line therapy in 226 patients with newly diagnosed advanced grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours, finding median progression-free survival of 22.8 versus 8.5 months (HR 0.276) and objective response in 43% versus 9.3%.
The overall survival story needs stating plainly, because it is often glossed over. The final NETTER-1 analysis, at a median follow-up of over six years, reported median overall survival of 48.0 months with lutetium-177 dotatate versus 36.3 months with high-dose octreotide, a numerically substantial 11.7-month difference, but with a hazard ratio of 0.84 and a p value of 0.30, it did not reach statistical significance. The trial was not powered for overall survival, and 36% of patients in the control arm crossed over to receive peptide receptor radionuclide therapy after progression, which would dilute any true difference. The reasonable conclusion is that survival benefit is plausible but unproven, and progression-free survival is where the demonstrated effect lies. Long-term observational data from the Erasmus Medical Centre in Rotterdam, covering 610 treated patients, reported median overall survival of 63 months from the first treatment cycle with an objective response rate of 39% and median progression-free survival of 29 months, and provided the best available long-term safety data including the rate of therapy-related myeloid neoplasms.
Evidence assessment
High-quality evidence
Two randomised phase 3 trials (NETTER-1 in progressive midgut neuroendocrine tumours and NETTER-2 in first-line grade 2/3 gastroenteropancreatic disease) with large, highly significant progression-free survival benefits, supported by a large long-term single-centre cohort, and full marketing authorisation in the EU, UK and US. All four citations verified against PubMed. The tier rests on progression-free survival; the null final overall survival analysis of NETTER-1 is reported prominently rather than buried.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors Preclinical only
Estimated 20-month progression-free survival 65.2% versus 10.8% with high-dose long-acting octreotide (HR 0.21); response rate 18% versus 3%. Established peptide receptor radionuclide therapy as a licensed treatment.
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial Preclinical only
Median overall survival 48.0 versus 36.3 months (HR 0.84, p = 0.30), not statistically significant, with 36% crossover from the control arm. No new safety signals; myelodysplastic syndrome occurred in 2% of treated patients.
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Preclinical only
Median progression-free survival 22.8 versus 8.5 months (HR 0.276) and objective response 43% versus 9.3%, extending peptide receptor radionuclide therapy into first-line use for higher-grade disease.
Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors Preclinical only
Objective response rate 39%, median progression-free survival 29 months and median overall survival 63 months from first treatment. Provided the key long-term safety dataset including rates of myelodysplastic syndrome and acute leukaemia.
Safety
Bone marrow suppression is the principal acute toxicity: lymphopenia is very common, and grade 3 or 4 thrombocytopenia, neutropenia and anaemia occur in a minority, generally recovering over weeks to months. Renal toxicity is the historic concern with radiolabelled peptides because the proximal tubule reabsorbs filtered peptide; this is mitigated by co-infusion of a positively charged amino acid solution (lysine and arginine), which competitively blocks megalin-mediated tubular reuptake. That amino acid infusion is itself the commonest cause of acute nausea and vomiting during treatment. Delayed haematological toxicity matters most: myelodysplastic syndrome and acute myeloid leukaemia have been reported in roughly 1.5-2.5% of treated patients in long-term series (2% in the final NETTER-1 safety analysis), typically two to five years after therapy. Hormonal crisis can occur in patients with functioning tumours as radiation-induced cell lysis releases stored bioactive amines. Hepatotoxicity, particularly with extensive liver metastases, secondary hypothyroidism, alopecia, fatigue and abdominal pain are reported. Male and female fertility may be impaired and radiation-protection precautions apply for a period after each infusion.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | EU marketing authorisation granted 26 September 2017 for unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours in adults, with a subsequent extension to adolescents. Licensed in Great Britain by the MHRA and recommended by NICE for unresectable or metastatic neuroendocrine tumours within its licensed indication. Restricted to centres with a nuclear medicine radiopharmaceutical licence. |
| United States | FDA approved January 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, including foregut, midgut and hindgut neuroendocrine tumours, in adults; the indication was subsequently extended to paediatric patients aged 12 years and older with somatostatin receptor-positive GEP-NETs. Administered as an intravenous infusion in a licensed nuclear medicine facility with concomitant amino acid renal protection. |
| WADA (sport) | Not on the WADA Prohibited List. It is a radiopharmaceutical with no anabolic, hormonal or masking activity; the peptide is administered in tracer-to-microgram quantities that produce no meaningful somatostatin agonist effect. |
Questions
Yes, and one of the few unambiguous ones in the radiopharmaceutical field. The targeting portion is octreotate, an eight-residue cyclic somatostatin analogue with a genuine disulfide-bridged peptide backbone. The DOTA chelator and the lutetium-177 are bolted on to it, but the biology of tumour targeting is entirely peptide-receptor pharmacology.
That is not proven. NETTER-1 showed a dramatic effect on progression-free survival (a hazard ratio of 0.21), but the final overall survival analysis gave 48.0 versus 36.3 months with a p value of 0.30. The trial was not powered for survival and 36% of control patients crossed over to the treatment after progressing, both of which make a real survival benefit harder to detect. Plausible, but not demonstrated.
Filtered peptide is reabsorbed by the proximal renal tubule through the megalin/cubilin receptor system, which would concentrate radioactivity in the kidney. Infusing a positively charged amino acid solution containing lysine and arginine competes for that reuptake and substantially cuts renal radiation dose. It is also the main reason patients feel nauseated during treatment.
The same targeting molecule is used both to image and to treat. Gallium-68 dotatate labelled for PET shows which tumours express somatostatin receptor 2 and how strongly; if the uptake is good, the identical peptide labelled with lutetium-177 delivers therapeutic beta radiation to exactly those sites. Diagnosis and therapy share one molecule.
Myelodysplastic syndrome and acute myeloid leukaemia have been reported in roughly 1.5 to 2.5% of treated patients across long-term series, typically appearing two to five years after therapy. It is a real risk that has to be weighed against the disease being treated, and it is one reason prior alkylating chemotherapy and baseline marrow reserve influence patient selection.